Your browser doesn't support javascript.
loading
Patients' health care resources utilization and costs estimation across cardiovascular risk categories: insights from the LATINO study.
Gavina, Cristina; Borges, Alexandra; Afonso-Silva, Marta; Fortuna, Inês; Canelas-Pais, Mariana; Amaral, Rita; Costa, Inês; Seabra, Daniel; Araújo, Francisco; Taveira-Gomes, Tiago.
Afiliación
  • Gavina C; Cardiology Department, Hospital Pedro Hispano-Unidad Local de Saúde Matosinhos, Matosinhos, Portugal.
  • Borges A; Department of Medicine, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Afonso-Silva M; Faculty of Medicine, UnIC, University of Porto, Porto, Portugal.
  • Fortuna I; Director of Planning, Contracting, and Management Control Service, Unidade Local de Saúde Matosinhos, Matosinhos, Portugal.
  • Canelas-Pais M; Health Economics & Outcomes Research / Real-World Evidence, Novartis Farma, Produtos Farmacêuticos SA, Porto Salvo, Portugal.
  • Amaral R; MTG Research and Development Lab, Porto, Portugal.
  • Costa I; MTG Research and Development Lab, Porto, Portugal.
  • Seabra D; Department of Community Medicine, Health Information and Decision, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Araújo F; MTG Research and Development Lab, Porto, Portugal.
  • Taveira-Gomes T; Department of Community Medicine, Health Information and Decision, Faculty of Medicine, University of Porto, Porto, Portugal.
Health Econ Rev ; 14(1): 73, 2024 Sep 12.
Article en En | MEDLINE | ID: mdl-39264520
ABSTRACT

BACKGROUND:

Atherosclerotic Cardiovascular Disease (ASCVD) is a global public health concern. This study aimed to estimate the healthcare resource utilization (HRU) and costs stratified by cardiovascular disease (CVD) risk categories using real-world evidence, in a regional population in Portugal.

METHODS:

This is a retrospective observational study, using data from Electronic Health Records between 2017 and 2021. Patients aged ≥ 40 years, and with at least one general practitioner (GP) appointment in the 3 years before 31st of December 2019, were included. CVD risk categories were determined based on 2021 ESC prevention guidelines. HRU encompassed hospital data (hospitalizations, outpatient and emergency room visits) and GP appointments. Total direct costs per patient were calculated based on the reference cost of the Portuguese legislation for payment methodology on Diagnosis-Related Groups (DRGs).

RESULTS:

Analysis of 3 122 695 episodes, revealed consistent HRU and costs across the five years. Very high-risk patients, showed higher HRU, particularly in hospital admissions. Costs tended to rise with higher CVD risk level. Very high-risk patients with ASCVD had higher costs for hospital admissions, while low-to-moderate risk patients had higher costs for GP visits. Despite a smaller proportion, very high-risk patients with prior ASCVD represent the highest costs per patient across healthcare settings (from 115€ in emergency visits to 2 673€ in hospitalizations), followed by very high-risk patients without prior ASCVD (ASCVD-risk equivalents).

CONCLUSION:

This study revealed a substantial HRU and costs by patients with very high CVD risk, particularly those with prior ASCVD. Moreover, ASCVD-risk equivalents emerge as notable consumers, emphasizing the importance of risk assessment and preventive measures in cost-effective management of these patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Health Econ Rev Año: 2024 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Health Econ Rev Año: 2024 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Alemania